GLP-1/Weight Loss

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

We map digital grids and autonomous routes, but what about the biological networks that define half of humanity? An Indian brand is using ancient wisdom to build new infrastructure for women's health.

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

Septerna's novel oral drug for hypoparathyroidism could end the tyranny of injections and supplements, but its success hinges on a bigger bet: a new system for drugging life's most difficult molecular targets.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

Beyond dividends, Stevanato Group's recent shareholder meeting signals a deeper shift in corporate governance, modernizing for stability and trust.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

Destination XL faces a perfect storm of declining sales, widening losses, and a crucial merger on the rocks. Can tech and new strategies counter market headwinds?

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.